Undernutrition is the single leading driver of TB mortality in India. The RATIONS trial (Bhargava et al., Lancet 2023) demonstrated that targeted nutritional supplementation reduces TB incidence among household contacts by 40 to 50%, and that a BMI below 16 is independently associated with a 4 to 5 fold increase in early mortality. Providing specific macro- and micro-nutritional targets alongside ATT is a critical standard of care, not optional supportive therapy.
Please complete the anthropometric data in the Clinical Pathway tab and synthesise the pathway to generate personalised nutritional targets.
Clinical Teachable MomentsThe "RIPE" Mnemonic for First-Line Toxicity
R - Rifampicin:Red/Orange secretions, Rapid CYP450 induction (most potent inducer in clinical medicine).
I - Isoniazid (INH):Injures Nerves (peripheral neuropathy - always give B6), Injures Hepatocytes (hepatitis).
P - Pyrazinamide:Polyarthralgia (hyperuricaemia), most Potent hepatotoxin of the four.
E - Ethambutol:Eye issues (retrobulbar optic neuritis, red-green colour blindness). Baseline visual acuity is mandatory.
⚠ Warning: FDC Quality in India
Bioavailability: Substandard generic Fixed-Dose Combinations (FDCs) in the private sector frequently fail to deliver adequate Rifampicin due to poor pharmaceutical formulation. If a patient is failing therapy on private sector FDCs, strongly consider switching to NTEP-supplied FDCs or prescribing individual loose drugs to guarantee absorption. This is a recognised cause of acquired drug resistance.
ATT-Induced Hepatitis: The Rechallenge Protocol
When to stop ALL ATT: AST/ALT exceeds 5x ULN (asymptomatic) or exceeds 3x ULN with hepatitis symptoms (nausea, vomiting, anorexia, jaundice).
Wait: Observe until LFTs normalise or fall below 2x ULN and symptoms resolve completely.
Rechallenge order: Reintroduce drugs sequentially, one at a time, with 3 to 7 days between each: R first (least hepatotoxic), then H, then Z last (most hepatotoxic). If hepatitis recurs with a specific agent, omit it permanently and substitute.
Never rechallenge Pyrazinamide if it was the identified culprit. Extend treatment duration instead.
DR-TB Classification Definitions (NTEP 2025)
DS-TB: Pan-susceptible to all first-line drugs.
H-Mono/Poly DR-TB: Resistant to Isoniazid (H), but definitively susceptible to Rifampicin (R). Requires FL-LPA for confirmation.
MDR/RR-TB: Resistant to Rifampicin (with or without H resistance), but susceptible to Fluoroquinolones (FQ).
Pre-XDR TB: MDR/RR-TB with additional resistance to any Fluoroquinolone.
XDR TB: Pre-XDR TB with additional resistance to Bedaquiline (Bdq) and/or Linezolid (Lzd).
Active Drug Safety Monitoring (aDSM)
The aDSM monitoring schedule will be generated based on the prescribed regimen once you synthesise the pathway from the Clinical Pathway tab.
NTEP strictly prioritises shorter all-oral regimens (BPaLM for MDR, BPaL for Pre-XDR). However, BPaLM/BPaL are strictly contraindicated in patients below 14 years or those with severe EPTB. The engine forcefully reroutes these phenotypes to the 18 to 20 month Longer Oral Regimen.
Dietary Bioavailability Traps
Drug absorption is highly variable based on gastric contents. Rifampicin Cmax is severely blunted by food, risking acquired resistance. Conversely, Bedaquiline absorption increases nearly two-fold when administered with a high-fat meal. This module dictates specific food timing instructions for every drug to prevent therapeutic failure.
NTEP Weight Bands
This engine uses the official NTEP 2024 adult weight bands: 25 to 39 kg (2 FDCs), 40 to 54 kg (3 FDCs), 55 to 69 kg (4 FDCs), and 70 kg and above (5 FDCs). Paediatric bands: 4 to 7 kg (1 FDC), 8 to 11 kg (2 FDCs), 12 to 15 kg (3 FDCs), 16 to 24 kg (4 FDCs). These are NOT arbitrary - they are calibrated to deliver therapeutic mg/kg doses across the population range.
⚠ Clinical Disclaimer: This engine mathematically executes NTEP India Guidelines (2024/2025). It cannot account for severe hepatic impairment (Child-Pugh C), terminal renal failure, complex drug-drug interactions (e.g., specific ART regimens), or pregnancy. Regimen modifications for these special populations require specialist consultation. Always verify calculated outputs against clinical judgement and institutional protocols.
Algorithm References & Evidence Base
Central Tuberculosis Division, Ministry of Health and Family Welfare, Government of India. National Guidelines for Management of Drug Resistant Tuberculosis. New Delhi: MoHFW; 2025.
Central Tuberculosis Division, Ministry of Health and Family Welfare, Government of India. Guidelines for Programmatic Management of Drug Susceptible Tuberculosis. New Delhi: MoHFW; 2024.
Central Tuberculosis Division, Ministry of Health and Family Welfare, Government of India. Guidance Document on Nutritional Care and Support for TB Patients in India. New Delhi: MoHFW; 2024.
Bhargava A, Bhargava M, Meher A, et al. Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial. Lancet. 2023;402(10405):927-940.
Nyang'wa BT, Berry C; TB-PRACTECAL Study Group. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022;387(25):2331-2343.
World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva: WHO; 2022.
How to Cite This Tool
AMA Style: Umakanth S. Comprehensive Tuberculosis Treatment Pathway. MEDiscuss. Published 2026. Accessed .
Vancouver Style: Umakanth S. Comprehensive Tuberculosis Treatment Pathway [Internet]. MEDiscuss.org; 2026 [cited ]. Available from:
